膀胱尿路上皮癌的膀胱内治疗
Intravesical therapy for urothelial carcinoma of the bladder.
作者信息
Manoharan M
机构信息
Department of Urology, University of Miami, Miami, FL, USA.
出版信息
Indian J Urol. 2011 Apr;27(2):252-61. doi: 10.4103/0970-1591.82846.
Abstract
Transurethral resection is an effective therapy for non-muscle-invasive bladder cancer. However, the high rates of recurrence and significant risk of progression in higher grade tumors mandates additional therapy with intravesical agents. In this review we discuss the role of various intravesical agents currently in use including the immunomodualtory agent BCG and chemotherapeutic agents. We discuss the current guidelines and the role of these therapeutic agents in the context of higher grade Ta and T1 tumors.
摘要
经尿道切除术是治疗非肌层浸润性膀胱癌的有效方法。然而，高级别肿瘤的高复发率和显著进展风险要求使用膀胱内灌注药物进行额外治疗。在本综述中，我们讨论了目前使用的各种膀胱内灌注药物的作用，包括免疫调节药物卡介苗（BCG）和化疗药物。我们还讨论了当前的指南以及这些治疗药物在高级别Ta和T1肿瘤治疗中的作用。
相似文献
1
Intravesical therapy for urothelial carcinoma of the bladder.
Indian J Urol. 2011 Apr;27(2):252-61. doi: 10.4103/0970-1591.82846.
2
Diagnosis and management of superficial bladder cancer.
Curr Probl Cancer. 2001 Jul-Aug;25(4):219-78. doi: 10.1067/mcn.2001.117539.
3
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
4
Best practice in the treatment of nonmuscle invasive bladder cancer.
Ther Adv Urol. 2012 Feb;4(1):13-32. doi: 10.1177/1756287211431976.
5
[The intravesical recurrence after 3-day consecutive intravesical instillation of pirarubicine hydrochloride (THP) following transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer].
Nihon Hinyokika Gakkai Zasshi. 2012 Jul;103(4):610-6. doi: 10.5980/jpnjurol.103.610.
6
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
7
[Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Aktuelle Urol. 2005 Aug;36(4):337-41. doi: 10.1055/s-2004-830188.
8
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Eur Urol. 2010 May;57(5):766-73. doi: 10.1016/j.eururo.2009.12.024. Epub 2009 Dec 18.
9
Intravesical chemotherapy in non-muscle-invasive bladder cancer.
Indian J Urol. 2015 Oct-Dec;31(4):297-303. doi: 10.4103/0970-1591.166446.
10
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
引用本文的文献
1
Cytotoxicity of Pb-labeled anti-PTK7 antibody in 2D adherent and 3D multicellular bladder cancer models.
EJNMMI Radiopharm Chem. 2025 Aug 30;10(1):58. doi: 10.1186/s41181-025-00382-3.
2
Tailoring treatment for elderly bladder cancer: a case report of personalized management of high-grade urothelial carcinoma with papillary features.
Front Oncol. 2024 Aug 6;14:1434795. doi: 10.3389/fonc.2024.1434795. eCollection 2024.
3
Human amniotic membrane inhibits migration and invasion of muscle-invasive bladder cancer urothelial cells by downregulating the FAK/PI3K/Akt/mTOR signalling pathway.
Sci Rep. 2023 Nov 6;13(1):19227. doi: 10.1038/s41598-023-46091-2.
4
Activation of autophagy triggers mitochondrial loss and changes acetylation profile relevant for mechanotransduction in bladder cancer cells.
Arch Toxicol. 2023 Jan;97(1):217-233. doi: 10.1007/s00204-022-03375-2. Epub 2022 Oct 10.
5
Tumour Behaviour of Low-Grade Papillary Urothelial Carcinoma: A Single-Centre Retrospective Study.
Cureus. 2021 Jun 29;13(6):e16012. doi: 10.7759/cureus.16012. eCollection 2021 Jun.
6
Fluid Shear Stress Induces Cell Cycle Arrest in Human Urinary Bladder Transitional Cell Carcinoma Through Bone Morphogenetic Protein Receptor-Smad1/5 Pathway.
Cell Mol Bioeng. 2018 Apr 17;11(3):185-195. doi: 10.1007/s12195-018-0523-1. eCollection 2018 Jun.
7
Systemic BCG-osis following intravesical BCG instillation for bladder carcinoma.
Clin Case Rep. 2017 Aug 15;5(10):1569-1572. doi: 10.1002/ccr3.1129. eCollection 2017 Oct.
8
Anti-tumor effect of Radix Paeoniae Rubra extract on mice bladder tumors using intravesical therapy.
Oncol Lett. 2016 Aug;12(2):904-910. doi: 10.3892/ol.2016.4698. Epub 2016 Jun 9.
9
Cortex Moutan Induces Bladder Cancer Cell Death via Apoptosis and Retards Tumor Growth in Mouse Bladders.
Evid Based Complement Alternat Med. 2013;2013:207279. doi: 10.1155/2013/207279. Epub 2013 Oct 24.
本文引用的文献
1
The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
Eur Urol. 2010 Mar;57(3):410-29. doi: 10.1016/j.eururo.2009.11.023. Epub 2009 Nov 13.
2
"Complete transurethral resection of bladder tumor": are the guidelines being followed?
Urology. 2010 Feb;75(2):365-7. doi: 10.1016/j.urology.2009.08.082. Epub 2009 Dec 6.
3
An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
Eur Urol. 2009 Aug;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24.
4
New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies.
Arch Ital Urol Androl. 2008 Dec;80(4):162-6.
5
The global burden of urinary bladder cancer.
Scand J Urol Nephrol Suppl. 2008 Sep(218):12-20. doi: 10.1080/03008880802285032.
6
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.
Eur Urol. 2008 Aug;54(2):303-14. doi: 10.1016/j.eururo.2008.04.051. Epub 2008 Apr 30.
7
Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
Urol Oncol. 2008 Nov-Dec;26(6):616-9. doi: 10.1016/j.urolonc.2007.10.016. Epub 2008 Feb 4.
8
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
9
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
Eur Urol. 2008 Jan;53(1):45-52. doi: 10.1016/j.eururo.2007.08.015. Epub 2007 Aug 20.
10
Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.
Biomed Pharmacother. 2007 Jul;61(6):299-305. doi: 10.1016/j.biopha.2007.05.004. Epub 2007 Jun 12.
Zotero 插件